ライフサイエンスコーパス: radium-223

1 docetaxel use on the efficacy and safety of radium-223.

2 s performed before crossover from placebo to radium-223.

3 MPCA study and before regulatory approval of radium-223.

4 terone acetate/prednisone, enzalutamide, and radium-223 ((223)Ra; for men with predominantly bone met

5 696 patients received one or more doses of radium-223; 403 (58%) of these patients had all six plan

6 response system to receive six injections of radium-223 (50 kBq/kg intravenously) or matching placebo

7 receive either six intravenous injections of radium-223 (50 kBq/kg) or matching placebo; one injectio

8 Patients received intravenous injections of radium-223, 50 kBq/kg (current recommendation 55 kBq/kg

9 PCA trial showed that radium-223 dichloride (radium-223), a targeted alpha-emitter, improved overall

10 Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone

11 Radium-223, an alpha-emitting radionuclide still under r

12 614 (67%) were randomly assigned to receive radium-223 and 307 (33%) placebo.

13 mia and neutropenia were similar between the radium-223 and placebo groups within both docetaxel subg

14 Radium-223 and sipuleucel-T also are options.

15 azitaxel, abiraterone acetate, enzalutamide, radium-223, and sipuleucel-T has increased the number of

16 We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the

17 terim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly impr

18 in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body wei

19 Our findings show that radium-223 can be safely combined with abiraterone or en

20 We assessed the effect of radium-223 compared with placebo in patients with castra

21 The benefit of radium-223 compared with placebo was seen in both doceta

22 Radium-223 dichloride (radium-223) selectively targets b

23 ignificantly longer in patients treated with radium-223 dichloride (radium-223) than in patients trea

24 from the phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), a targeted alpha-emi

25 Radium-223 dichloride (radium-223), an alpha emitter, se

26 ncreasing with the adoption into practice of radium-223 dichloride for the treatment of bone metastas

27 itionally, the radioactive therapeutic agent radium-223 dichloride has been recently approved in pati

28 Investigations involving alpha-emitting radium-223, endothelin-A receptor antagonists atrasentan

29 occurred in 202 (33%) of 614 patients in the radium-223 group and 116 (38%) of 307 patients in the pl

30 ebo group) and 395 (43%) had not (262 in the radium-223 group and 133 in the placebo group).

31 ved previous docetaxel treatment (352 in the radium-223 group and 174 in the placebo group) and 395 (

32 ficacy at the prespecified interim analysis, radium-223 improved overall survival.

33 of skeletal-related events (SREs), but only radium-223 improves survival.

34 Radium-223 is effective and well tolerated in patients w

35 ated events, whereas the radiopharmaceutical radium-223 is shown to reduce the incidence of symptomat

36 val was also longer in patients who received radium-223 plus abiraterone, enzalutamide, or both (medi

37 months, 12-16), and in patients who received radium-223 plus denosumab (median NA, 15 months-NA) than

38 Radium-223 prolonged median overall survival compared wi

39 Denosumab and radium-223 reduce the risk of skeletal-related events (S

40 Radium-223 dichloride (radium-223) selectively targets bone metastases with hig

41 Radium-223 should be considered as a treatment option fo

42 nalysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.

43 incidence of grade 3-4 thrombocytopenia with radium-223 than with placebo (31 [9%] of 347 patients vs

44 t symptomatic skeletal event was longer with radium-223 than with placebo (median 15.6 months [95% CI

45 patients treated with radium-223 dichloride (radium-223) than in patients treated with placebo.

46 investigated safety and overall survival in radium-223 treated patients in an early access programme

47 Radium-223 treatment did not seem to significantly reduc

48 ated the effect of previous docetaxel use on radium-223 treatment for the primary endpoint of overall

49 symptomatic skeletal event was reduced with radium-223 versus placebo in patients with previous doce

50 deaths had occurred, assessed the effect of radium-223 versus placebo on survival.

51 Radium-223 was associated with low myelosuppression rate

52 15 months-NA) than in patients who received radium-223 without denosumab (median 13 months, 12-NA).